



## **Vijaya Diagnostic Centre Limited**

Q1 FY23 Earnings Presentation
August 09, 2022

### **Safe Harbour**



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Vijaya Diagnostic Centre Limited (the 'Company')**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.






# **Q1 FY23 Financial Performance**

## **Q1 FY23 – Performance Snapshot**





### **Management comment**





# Commenting on the Q1FY23 results performance, Ms. Suprita Reddy, CEO at Vijaya Diagnostic Centre Ltd. said:

"I am pleased to share that we have commenced the fiscal on a positive note. During Q1FY23, Vijaya was able to capitalize on the healthy recovery in demand from its customers for non-covid, radiology and wellness businesses. A notable month-on-month improvement across our key business parameters was witnessed during this period and we expect this trend to continue in the upcoming quarters as well.


Vijaya has achieved an important milestone of successfully establishing its 100<sup>th</sup> centre by opening five new centres during Q1FY23. The Company remains excited for its upcoming 10,000 sq.ft facility at Rajahmundry which is expected to be inaugurated soon. Additionally, we made considerable progress on our upcoming 16,000 sq.ft. Punjagutta centre which is scheduled to be launched in the coming months. We remain excited about these state-of-the-art facilities that are well equipped with advanced radiology and will offer a wide range of integrated diagnostics services to our consumers. Overall, our expansion and other growth initiatives are progressing as per plan.


Our endeavor remains on strengthening our leadership position in key markets as we move into the prepandemic environment. Looking ahead, we believe that our integrated diagnostics offerings, B2C business model, robust financial position, and strong brand salience in our core markets, should assist us to withstand any near-term challenges. Additionally, we are confident that these inherent strengths would go a long way in creating sustainable value for all our stakeholders."


## **Key Financial Highlights – Q1 FY23**



(INR Mn)










## Revenue Mix – Q1 FY23




(INR Mn)









## Q1 FY23 - Financial and Operational Discussions (Y-o-Y)



- Revenue from Operations decreased by 14.9% YoY to Rs. 1,043.6 Mn, Non-COVID Revenues grew by 11.6%
   YoY
  - Decline in revenue largely on account of decrease in COVID business. Q1FY23 witnessed a transition in the revenue mix profile from COVID to Non-COVID. This resulted in the Non-COVID business revenues registering a growth of 11.6% YoY and COVID revenues declining by 90.0% YoY
  - Radiology business stood higher at 35.7% as against 32.1% in Q1FY22 positively contributing to the Company's non-covid business
  - O Wellness share in Q1FY23 was up at 9.6% as against 4.0% in Q1FY22
    - Witnessed positive business momentum in Wellness segment achieving Pre-COVID levels
- Revenue composition from B2C segment continued to stay strong at 95.0%
- EBITDA stood at Rs. 398.9 Mn. EBITDA margin for the quarter was 38.2%
  - Lower revenues and incremental expenses for upcoming facilities impacted margin performance
  - As new facilities start contributing to performance, the Company anticipates improvement in operating margins
- PAT stood at Rs. 174.5 Mn. translating into a PAT margin of 16.7%


Financial
Performance
Q1 FY23

## Q1 FY23 – Key Developments



### Healthy month-on-month uptick in operational performance

- During Q1FY23, the Company registered growth on a month-on-month basis on the back of non-COVID, radiology and wellness businesses
- As the environment normalizes, the non-COVID offerings would continue to shift to pre-pandemic levels




### **VDCL** launches its 100<sup>th</sup> Centre


- The Company made encouraging progress on its network expansion plans by adding 5 new centres including 1 Hub
- The state-of-the-art 10,000 sq.ft. new facility at Rajahmundry, Andhra Pradesh is expected to be inaugurated during August 2022 itself
- Considerable progress was made on the upcoming 16,000 sq.ft. Punjagutta, Hyderabad centre scheduled to be launched in the coming months
  - The state-of-the-art Punjagutta facility would be the first diagnostic centre in South India to have advanced radiology modalities like MRI 3 Tesla and Dual Source CT Scan
  - Additionally, the centre will also be well equipped with other advanced radiology equipment's like PET CT and Gamma Camera
- Overall, VDCL remains on track to open over 15 new centers in FY23




## **Key Financial Highlights**











- Cash flow from Operations stood at Rs. 394 mn. as on June 30, 2022
- Cash and Cash Equivalents stood at Rs. 2,354 mn. as on June 30, 2022
- Working Capital Days continues to remain negative at -9 in Q1FY23


Note 1: Quarterly Revenue figures are annualized


## **Key Operational Highlights**














Company recorded steady growth in No. of tests on YoY basis led by Non-COVID customers in Q1FY23

## **Consolidated Profit & Loss Account – Q1 FY23**



(INR Mn)

Particulars	Q1 FY23	Q1 FY22	Y-o-Y	Q4 FY22	Q-o-Q
Revenue from operations	1,043.6	1,226.9	-14.9%	1,162.0	-10.2%
Cost of materials consumed	130.3	210.8	-38.2%	178.8	-27.1%
Employee benefits expense	194.8	161.5	20.6%	192.0	1.5%
Other expenses	319.6	286.0	11.7%	312.7	2.2%
EBITDA	398.9	568.6	-29.8%	478.6	-16.6%
EBITDA Margin (%)	38.2%	46.3%	-810 bps	41.2%	-300 bps
Other income	27.7	32.8	-15.7%	31.9	-13.2%
Depreciation and amortization expense	141.8	119.2	18.9%	152.8	-7.2%
EBIT	284.9	482.2	-40.9%	357.7	-20.4%
Finance costs	47.7	40.0	19.1%	43.4	9.9%
Profit before Tax	237.2	442.2	-46.4%	314.3	-24.5%
Tax expenses	61.6	108.9	-43.4%	75.5	-18.3%
Profit before Minority Interest	175.6	333.3	-47.3%	238.8	-26.5%
Minority Interest	1.1	3.6	-70.0%	1.7	-37.5%
Profit after Tax (PAT)	174.5	329.7	-47.1%	237.1	-26.4%
PAT Margin (%)	16.7%	26.9%	-1,020 bps	20.4%	-370 bps
EPS – Basic (INR)*	1.7	3.2	-47.0%	2.3	-26.4%

\*Not annualized





# **Company Overview**

## Vijaya at a Glance



Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 100 state-of-the-art centres spread across 17 cities



#### Mission

Our Mission is to make the patient's medical journey faster, more transparent and more accurate. We are committed to deliver exceptional diagnostic solutions to every patient and physician



#### Vision

Our Vision is to provide reliable and accurate diagnostic services to our customers, at affordable prices, in a customer-centric manner. We strive to provide the best service possible. We are continually raising our own bar through the latest technology, continuous improvement and recruitment of high calibre technicians and professional



### 40+

**Years of Experience** 

Experience in delivering Quality Diagnostic Service at affordable prices



### 100

Centres

State-of-the-art Facilities with Best-in-class Technology



Quality



### **17**

Cities across India

Largest integrated player in South India



### 200+

**Doctors** 

Radiologists, Pathologists & Microbiologists



Reliable & Accurate Diagnostics



### ~3.6 Mn

Trusted by every Age group

**Footfalls** 



### ~9.3 Mn

Tests

Most preferred Diagnostic Centre



at Affordable **Prices** 

Footfalls & Tests for 12 months ending Mar 2022 The Pioneers in Diagnostic Medicare...


## **Our Journey**



**Successfully listed on Indian Stock** 

Exchanges (NSE & BSE)

First independent diagnostic centre in Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare Pvt. Ltd



**Limited and Kedaara Capital** 

Alternative Investment Fund -

**Kedaara Capital AIF1** 

\*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

Centre - India by Times

**Healthcare Achievers Group** 


First independent diagnostic centre

in South India to offer PET CT from

Wipro GE Healthcare Pvt. Ltd.


## At the Forefront of Introducing New Technologies





## **Our Pillars of Strength**







## **Indian Diagnostics Market expected to Grow at a Healthy Trajectory**



### **Indian Diagnostics Market**


(INR Bn)






### Segment-wise breakup of Indian Diagnostic Market






## One of the leading players in India's high growth diagnostics market





#### **Growth Drivers:**


- Rising NCDs in the states
- Increasing share of aged population
- Rising health awareness
- Increasing health insurance penetration
- Conducive government healthcare schemes



NCD: Non Communicable diseases Source: CRISIL Report

## Integrated Diagnostic service provider with extensive network...





Flagship Centre = Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT)

**Hubs** = Lab Samples Collection + Basic Radiology + Advanced Radiology (MRI / CT Scan / SPECT) **Spokes** = Lab Samples Collection + Basic Radiology

Basic Radiology = ECG / X-ray / USG / Mammography / BMD / TMT / 2D Echo / EEG / ENMG / Endoscopy, etc.

## ...offering One-Stop Solutions for Pathology & Radiology





## High brand recall driving customer stickiness



### Customer Centric Approach Quality Diagnostic Services



**Higher brand recall** 

High share of walk-in customers


Sticky individual customer


### "One of the Best Healthcare Brands 2021"

by The Economic Times in 2021

# "For excellence in Quality and Accuracy"


under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics Leadership Summit in 2021





## **Robust Technical Capabilities with State-of-the-art IT Infrastructure**





### **Key Suppliers**











- · Long standing relationship with medical technology vendors
- At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

### **Advanced Software to Manage Clinical Data**





#### Front end IT infrastructure enabling...



**Standardization** across our operations



Closely track key performance metrics and maintain the **Turn-Around Time (TAT)** 

Communication Systems (PACS)



Reduce incidence of errors due to **Low Human Intervention** 



Provide **Uniform Experience** to customers from booking appointments to accessing reports online



Monitor Technical Operations

The Pioneers in Diagnostic Medicare...

23

## **Experienced Board of Directors**





#### Dr. S Surendranath Reddy - Executive Chairman

- Founder of Vijaya with 40+ years of experience in building Vijaya as South India's largest integrated diagnostic chain
- Holds Bachelor's degree in Medicine and Provisional degree of Doctor of Medicine in Radiology



### **Dr. D Nageshwar Reddy -** Non-executive, Independent Director

- Chairman of Asian Institute of Gastroenterology (AIG), Hyderabad
- Awarded Padma Shri and Padma Bhushan by Government of India
- D.M in Gastroenterology from PGIMER Chandigarh



S Geeta Reddy - Non-Executive Director

- Enrolled as advocate with Andhra Pradesh High Court in 1986
- Holds a Bachelor's degree in Law from Osmania University



#### Shekhar Prasad Singh - Non-executive, Independent Director

- Ex-Chief Secretary to Government of Telangana
- Retired IAS officer of 1983 batch



#### Sunil Chandra Kondapally - Executive Director

- Been with Vijaya since 2002 and 17+ years of experience in healthcare
- Holds Bachelor's degree in Electrical Engineering from Florida State University



#### Satyanaryana Murthy Chavali - Non-executive, Independent Director

- Ex-CEO of Aurigene Discovery Technologies Ltd.
- Holds BTech from IIT, Madras and MBA from IIM, Bangalore



#### Dr. Manjula Anagani - Non-executive, Independent Director

- Clinical Director and Head of Department of centre of women and childcare at Care hospitals
- Awarded Padma Shri by Government of India
- MD in Obstetrics and Gynecology from N.T.R. University of Health Sciences

### **Strong Management Team**





Dr. S. Surendranath Reddy

**Executive Chairman** 

- 40+ years of experience in building Vijaya as South India's largest integrated diagnostic chain
- Holds Bachelor's degree in Medicine and Provisional degree of Doctor of Medicine in Radiology
- He is a life member of the Indian Radiological and Imaging Association.



Mr. Sunil Chandra Kondapally

**Executive Director** 

- With Vijaya since incorporation and experienced in operations, quality accreditation, finance, marketing and network expansion departments
- 17+ Years of experience in healthcare industry & founded Trikona Pharmaceuticals Pvt. Ltd. (2016) and QPS Bioserve India Pvt. Ltd. (2004)
- Holds bachelor's degree in electrical engineering from Florida State University



Ms. Suprita Reddy

**Chief Executive Officer** 

- With Vijaya since 2003 and heads overall strategy, clinical excellence, operations and expansion of the company
- Awarded Women Leadership Award in Healthcare by ABP in 2019
- Holds bachelors degree in commerce from Osmania University



Mr. Narasimha Raju K.A

Chief Financial Officer

- Associated with Vijaya from June 2017 to Nov 2020 and rejoined in March 2021
- 14+ years of experience in audit, financial reporting, regulatory compliance and accounting advisory
- Previously worked with SR Baltliboi & Co., NSL Renewable Power Pvt. Ltd. etc
- Holds bachelor's degree of commerce from Osmania University and member of the Institute of Chartered Accountants of India



Ms. Anusha Kanumuru

Company Secretary & Compliance Officer

- 12 + years of experience in handling works relating to public issue(s), private placement(s), merger(s), foreign investment, listing formalities with the Stock Exchanges, Company Law, FEMA and Stock Exchange Compliances including regulatory approvals
- Associate member of ICSI and holds Bachelor's degree in Commerce and Corporate Affairs
- Previously worked with Aurobindo Realty, IVRCL Ltd etc

### Awards & Accolades



## One of the Best Healthcare Brands 2021



**2021**Presented by
The Economic
Times

#### Indo Global Award for Healthcare Excellence



Presented by
Indian Economic
Development &
Research Association

#### Company of the Year -Healthcare



**2021**Presented by
TV9 Network and SAP

## Leading Diagnostic Chain of the Year



**2021**Presented by
Diagnostic Leadership
Summit

India's Greatest Leaders 2020-21 Ms. Suprita Reddy - CEO



2021 Presented by United Research Services

## India's Greatest Brands 2020-21 Pride of Nation



**2021**Presented by
United Research
Services

### Leading Diagnostics with Excellence in Quality & Safety



2021
Presented by
Diagnostic
Leadership Summit

## Most Trusted and Best Quality Diagnostic services in India



2020 Presented by Times Healthcare Achievers

#### Healthcare Entrepreneur of the Year – Dr. Surendra Reddy



**2019**Presented by
Six Sigma
Healthcare

# Fastest Growing Brands (Pride of the Nation)



2019
Presented by
United Research
Services

## Best Diagnostic Centre of the Year



2019
Presented by
Times Healthcare
Achievers

## Leading Chain of Diagnostics & Imaging



2019
Presented by
Indian Medical
Association,
Telangana state and
Messe India

## Best Diagnostic Service Provider of the Year



2019 Presented by Six Sigma Healthcare

## Most Trusted Diagnostic Centre of the Year



2019
Presented by
Indo-Arab
Leaders
Summit &
Awards


### Telangana Healthcare Leadership Awards



2018
Presented by
Telangana
Government

## **Shareholding Pattern as of 30th June 2022**





Marquee Institutional Investors

Fidelity Group

Wasatch Advisors

Axis Mutual Fund

Aberdeen Standard Investments

Nippon Life India Asset Management

Aditya Birla Sun Life Asset Management

Abu Dhabi Investment Authority

**DSP Mutual Fund** 

As on 30<sup>th</sup> June 2022

DII's: Mutual Funds, AIF's and QIB's

Others: Retail, Bodies Corporate and others






# **Strategy Going Forward**

## Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh








## **Expand in Adjacent Geographies & East India**



### **South India Strategy**

- Expand in concentric circles given our hub and spoke model
- Establish presence in adjacent geographies
- Identified key cities and towns which are underserved and our brand is wellregarded
- Wider geographic reach will expand our customer base leading to better profitability by leveraging our infrastructure



### **East India Strategy**


- Expand presence in East India given growing demand
- Replicate our successful hub and spokes model in East India
- Established a hub in Kolkata and plan is to set up additional diagnostic centres around it
- Hence, Kolkata to be our focus area for medium to long term growth

AP: Andhra Pradesh

## **Continued Focus on Providing Customer Centric Services and Offerings**







#### **Key Drivers**

- Increasing chronic and lifestyle diseases
- Corporate tie-ups
- Increasing disposable income
- Increasing service offerings

#### **Our Strategy**

- Increase diagnostic services by offering additional preventive and wellness services through adoption of new cutting-edge diagnostic testing technology
- Providing home collection services and point-of-contact testing to complement walk-in
- Expand specialty tests, disease specific profiles and provide customized packages
- Grow our corporate customer base by catering to their needs
- Expansion of chronic disease management and wellness programs






# **Financial & Operational Highlights**

## **Robust Operational Metrics**








### Footfalls (Mn)



### Tests Performed (Mn)



### Test per Footfall (Nos)





### Revenue per Test (INR)




### Revenue per Footfall (INR)





## **Consistent Financial Performance**





(INR Mn)











## **Sustainable Cash Generation & Increasing Return Ratios**









## **Annexure**

## **Consolidated Profit & Loss Account**



(INR Mn)

Particulars	FY22	FY21	FY20	FY19
Revenue from operations	4,624	3,767	3,388	2,926
Cost of materials consumed	715	571	439	405
Employee benefits expense	707	574	624	539
Other expenses	1,165	962	999	901
EBITDA	2,037	1,660	1,326	1,081
EBITDA %	44.1%	44.1%	39.1%	37.0%
Other income	128	118	154	104
Depreciation and amortization expense	527	505	492	396
EBIT	1,638	1,274	988	789
Finance costs	165	152	154	135
Profit before Tax	1,474	1,121	834	653
Tax expenses	367	270	209	190
Profit after Tax before Minority Interest	1,107	851	625	463
Minority Interest	10	6	0	4
Profit after Tax	1,097	845	625	459
PAT %	23.7%	22.4%	18.5%	15.7%
EPS – Basic (INR)	10.76	8.28	6.13	4.50

## **Consolidated Balance Sheet**



(INR Mn)

Assets	Mar-22	Mar-21	Mar-20	Mar-19
NON-CURRENT ASSETS	4,436	3,022	2,959	2,689
Property, plant and equipment	1,966	1,358	1,398	1,43
Capital work-in-progress	341	82	93	2
Goodwill	53	53	53	6
Other intangible assets	14	6	10	
Right of use asset	1,672	1,260	1,254	1,07
ntangible assets under development	1	12	4	
Financial assets				
- Investments	0	0	0	
- Other financial assets	75	122	55	4
Deferred tax assets	89	61	16	1
ncome tax assets	2	6	9	
Other assets	223	61	67	
CURRENT ASSETS	2,699	2,388	1,865	1,37
nventories	43	26	28	2
Financial assets				
- Investments	542	276	547	68
- Trade receivables	98	64	80	9
- Cash and cash equivalents	110	67	556	9
- Bank balances other than Cash and cash equivalents	1,813	1,876	626	43
- Loans	0	0	1	
- Other financial assets	51	52	5	2
Other current assets	41	27	22	1
TOTAL ASSETS	7,135	5,409	4,824	4,06

EQUITY AND LIABILITIES	Mar-22	Mar-21	Mar-20	Mar-19
EQUITATIO EMBIETIES	Widi-22	Mai 21	Widi 20	Widi 13
EQUITY	4,695	3,592	2,741	2,069
Equity share capital	102	45	45	45
Instruments entirely equity in nature	-	-	-	24
Other equity	4,593	3,547	2,696	2,000
NON-CURRENT LIABILITIES	1,778	1,377	1,494	1,422
Financial liabilities				
- Borrowings	0	33	221	315
- Lease liabilities	1,703	1,265	1,196	1,034
- Other financial liabilities	0	2	9	19
Provisions	74	77	67	53
Other liabilities	1	1	1	1
CURRENT LIABILITIES	661	440	589	572
Financial liabilities				
- Borrowings	6	12	13	20
- Lease liabilities	126	101	88	73
- Trade payables	216	222	217	218
- Other financial liabilities	248	61	224	204
Income tax liabilities	9	16	15	15
Provisions	21	7	11	11
Other liabilities	35	20	21	31
TOTAL EQUITY AND LIABILITIES	7,135	5,409	4,824	4,063

## **Consolidated Cash Flow Statement**



(INR Mn)

Particulars	Mar-22	Mar-21	Mar-20	Mar-19
Cash Flow from Operating Activities				
Profit before Tax	1,474	1,121	834	653
Adjustment for Non-Operating Items	572	534	492	431
Operating Profit before Working Capital Changes	2,046	1,655	1,326	1,084
Changes in Working Capital	-67	-46	-32	8
Cash Generated from Operations	1,975	1,609	1,294	1,092
Less: Direct Taxes paid	-399	-312	-233	-187
Net Cash from Operating Activities	1,580	1,297	1,061	905
Purchase and construction of property, plant and building (net)	-1,223	-312	-375	-591
Investments (net)	-127	-1,033	11	-314
Others	120	47	57	6
Cash Flow from Investing Activities	-1,226	-1,298	-306	-898
Cash Flow from Financing Activities	-306	-488	-295	-72
Net increase/ (decrease) in Cash & Cash equivalent	44	-489	460	-65
Cash & Cash Equivalents at the beginning of the period	67	556	96	161
Cash & Cash equivalents at the end of the period	110	67	556	96

### **Cash and Cash Equivalents**

Particulars	Mar-22	Mar-21	Mar-20	Mar-19
Investments*	543	335	547	688
Cash and cash equivalents	110	67	556	96
Bank balances other than Cash and cash equivalents	1,813	1,876	626	430
Total	2,467	2,277	1,729	1,215





## **THANK YOU**

### Company

Vijaya Diagnostic Centre Limited (VDCL)



Mr. Siva Rama Raju – Head of Strategy +91 90597 00749 / +91 99485 95555

> <u>sivaramaraju.v@vijayadiagnostic.in</u> <u>ir@vijayadiagnostic.in</u>

> > www.vijayadiagnostic.com

### **Investor Relations Advisors**

**Citigate Dewe Rogerson (CDR India)** 

Mr. Anoop Poojari / Mr. Devrishi Singh

| Citigate Dewe Rogerson | Tel: +91 98330 90434 |

+91 98205 30918

anoop@cdr-india.com devrishi@cdr-india.com

#6-3-883/F, Ground Floor, FPAI Building, Punjagutta, Officers Colony, Near Topaz Building, Hyderabad-500082, Telangana, India.